Edgewise Therapeutics Inc. (EWTX) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Edgewise Therapeutics Inc. (NASDAQ: EWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $38.11 (-2.03% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.9%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
Per EWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710072), Edgewise Therapeutics Inc. generated $535.9M in revenue (+20.5% YoY), -$167.8K in net income, and -$144.1M in free cash flow against $552.6M in total assets and $13.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
20D Institutional Volume Accumulation (±9.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While EWTX currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($41.01) and Max Pain ($40.02) forces dealer call-delta covering toward $50.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Edgewise Therapeutics Inc. (EWTX) dropped -2.03% to $38.11, trading at 67% of its 52-week range ($16.7 – $48.51). Stretched risk/reward at current multiples (-32% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EWTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EWTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Edgewise Therapeutics Inc. (EWTX) ranks #433 by composite RQD confidence (41/100, grade D-) and #173 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with EWTX at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EWTX
ACTIVE
Edgewise Therapeutics Inc. | D- | 41/100 | — | — | -31.9% | -2.03% | $4.22B | Benchmark Subject |
| LEGN Legend Biotech Corporation | C- | 60/100 | 32.8x | — | 9.9% | -2.45% | $4.21B | /legn-vs-ewtx → |
| INDV Indivior Pharmaceuticals Inc. | D | 51/100 | 19.8x | 80.2% | 62.2% | +0.34% | $4.17B | /indv-vs-ewtx → |
| LQDA Liquidia Corporation | D- | 36/100 | — | — | -12.6% | -7.12% | $4.03B | /lqda-vs-ewtx → |
| ARQT Arcutis Biotherapeutics Inc. | D+ | 54/100 | — | 90.2% | -3.0% | -2.53% | $4.03B | /arqt-vs-ewtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Edgewise Therapeutics Inc. (EWTX) reported GAAP revenue of $535.9M (+20.5% vs. FY2024 revenue of $444.7M , and +67.4% cumulative change since FY2023) , GAAP net income of -$167.8K, operating cash flow of -$143.8M, and free cash flow of -$144.1M (-30.6% YoY). On the balance sheet, EWTX closed FY2025 with $552.6M in total assets against $13.7M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $535.9M | -$167.8K | -$143.8M | -$144.1M | $552.6M | $13.7M |
| FY2024 (FY) | 2024-12-31 | $444.7M | -$133.8K | -$109.0M | -$110.3M | $486.8M | $12.4M |
| FY2023 (FY) | 2023-12-31 | $320.2M | -$100.2K | -$91.9M | -$91.9M | $2.32B | $543.9M |
As of 2026-11-03, Edgewise Therapeutics Inc. (NASDAQ: EWTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $38.11 (-2.03% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EWTX carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -31.9%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and INDV (Indivior Pharmaceuticals Inc.) posts a D grade (51/100 RQD, P/E 19.8x, ROIC 62.2%, cap $4.17B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).
Per EWTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710072), Edgewise Therapeutics Inc. generated $535.9M in revenue (+20.5% YoY), -$167.8K in net income, and -$144.1M in free cash flow against $552.6M in total assets and $13.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
EWTX last traded at $38.11 (-2.03% on volume of 1,083,640 shares), positioning the stock -7.07% below its 50-day simple moving average ($41.01) and +4.55% above its 200-day simple moving average ($36.45). Across its 52-week range of $16.70 to $48.51, EWTX sits at the 67.3% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($34.49 to $41.73).
Edgewise Therapeutics Inc. (EWTX) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $38.11 (-2.03% 1D, market capitalization $4.22B).
Edgewise Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the company currently reports no commercial revenue.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Edgewise Therapeutics Inc. (EWTX) reported $535.9M in annual revenue (up from $444.7M in FY2024, +20.5% YoY) and -$167.8K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($320.2M revenue, -$100.2K net income) through FY2025, EWTX scaled operating cash flow to -$143.8M and free cash flow to -$144.1M, backed by $552.6M in total assets against $13.7M in total debt.
The one quantified sector-level linkage is the liquidity sensitivity described above: a 2.21x beta to net liquidity means funding conditions and risk appetite for long-duration biotech equities are the main 2nd-order transmission channel. Watch for any deterioration in high-yield spreads or a continued decline in net liquidity, as either would amplify pressure on a company with negative free cash flow.
Real-time company headlines, analyst actions, and sector developments for Edgewise Therapeutics Inc. (EWTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Edgewise Therapeutics Inc. (EWTX) market action, institutional positioning, and fundamental catalysts.
Don't sleep on EWTX's setup in Health Care. Low leverage (Debt/Equity 0.02) and a 25 forward P/E on a Phase 3 hypertrophic cardiomyopathy program with continued buy ratings from RBC and H.C. Wainwright.. Beta of 1.1 means it moves fast when momentum turns, and the 5-pillar RQD gauge (41/100) backs up the fundamental quality.
@FadeTheHype Fair point on 25.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Here is the bear case nobody on the bull side wants to address on EWTX: Negative free cash flow in every reported period, ROIC of -31.9%, and a 2.21x liquidity beta leave the stock exposed if funding conditions tighten.. At 25.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).